Calquence Had Fewer Heart Complications Than Imbruvica in CLL Treatment
Fewer patients with chronic lymphocytic leukemia experienced cardiac toxicities with Calquence than those treated with Imbruvica, research showed.
Source: curetoday.com
Rupal Oquinn News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Rupal Oquinn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Rupal Oquinn Today - Breaking & Trending Today
Acalabrutinib Is Associated With Low Frequency of Cardiac Events Across 3 Randomized Trials in CLL
Administration of acalabrutinib to patients with chronic lymphocytic leukemia with or without cardiovascular disorders at baseline results in a numerically decreased incidence of overall treatment-related cardiac toxicities and a comparable safety profile vs comparator CLL therapies such as ibrutinib.
Source: onclive.com